The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient’s own immune system.
| |
| [16-November-2017] |
| SAN DIEGO, November 16, 2017 /PRNewswire/ -- 18 months ago, Regen BioPharma (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient’s own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders “The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid arthritis, lupus, colitis and many other autoimmune diseases,” says David Koos, Ph.D., Chairman and CEO of Regen. “Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection.” There are currently about 9 companies working on activating immune checkpoints, but Regen appears to be the sole company known to be working on utilizing small molecules to activate immune checkpoints (https://www.biocentury.com/bc-innovations/strategy/2017-08-10/how-immuno-oncology-targets-are-spawning-new-therapies- ). About Regen BioPharma Inc.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com. Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer 619-702-1404 Phone 619-330-2328 Fax http://www.regenbiopharma.com david.koos@regenbiopharma.com
SOURCE Regen BioPharma Inc. | ||
Company Codes: Bloomberg:RGBP@US, RICS:RGBP, ISIN:US75886M1027, OTC-QB:RGBP, OTC-QB:RGBPP, OtherOTC:RGBP |
